The partnership will integrate Molecular Health’s digital drug development platform into Axxam's integrated early drug ...

Pairing data-driven clinical-molecular insights with biological validation to identify relevant drug targets and confirm ...

In the past, most targeted drug development efforts relied on single biomarkers, but cancer is far more complex. BostonGene’s ...

Molecular Health & Axxam ink partnership to bolster discovery of innovative targets indrug development: Milan, Italy Thursday, June 5, 2025, 10:00 Hrs [IST] Axxam S.p.A., a premie ...

The Platform Technology Designation, which precedes the current FDA leadership, is designed to streamline the drug ...

Sortera Bio, a Cambridge biotech based on IP developed at the MRC Laboratory of Molecular Biology, has attracted big hitting ...

Renovaro Inc. (NASDAQ:RENB) declared that the U.S. Patent and Trademark Office has granted its subsidiary BioSymetrics a ...

The cell line development market is projected to grow at a CAGR of 3.9%, increasing from USD 3,392.5 Million in 2025 to ...

Synthesis is at the heart of drug discovery and development. The industry has increasingly demanded higher quality clinical candidates and has sought to exploit less druggable biological targets.

A Hong Kong University of Science and Technology (HKUST) research team has developed a catalytic enantioselective type II ...

Collaboration combines Nuclera's eProtein Discovery System, which accelerates protein expression, purification and ...